Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Status:
Not yet recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
The study will aim to estimate the efficacy of apremilast compared with placebo in the
treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18
years of age.